CD274 and neoplasm: In both the full EORTC QLQ-C30 evaluable population (Fig. 3) and the patients with tumor PD-L1 expression ≥1% (Supplementary Fig. 1), the median TTCD of HRQoL was not reached for either nivolumab or placebo for EORTC QLQ-C30 global health status/QoL, physical functioning, or role functioning.